Human beta -Filamin Is a New Protein That Interacts with the Cytoplasmic Tail of Glycoprotein Ibalpha *

Toshiro TakafutaDagger , Guoxin WuDagger , George F. Murphy§, and Sandor S. ShapiroDagger

From the Dagger  Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College and § Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We have cloned and sequenced a 9.4-kilobase cDNA specifying a new 280-kDa protein interacting with the cytoplasmic tail of glycoprotein (Gp) Ibalpha and showing considerable homology to actin-binding protein 280 (ABP-280) and chicken retinal filamin. We term this protein human beta -filamin. The gene for beta -filamin localizes to chromosome 3p14.3-p21.1. beta -Filamin mRNA expression was observed in many tissues and in cultured human umbilical vein endothelial cells (HUVECs); only minimal expression was detected in platelets and the megakaryocytic cell line CHRF-288. Like ABP-280, beta -filamin contains an NH2-terminal actin-binding domain, a backbone of 24 tandem repeats, and two "hinge" regions. A polyclonal antibody to the unique beta -filamin first hinge sequence identifies a strong 280-kDa band in HUVECs but only a weak band in platelets, and stains normal human endothelial cells in culture and in situ. We have confirmed the interaction of beta -filamin and GpIbalpha in platelet and HUVEC lysates. In addition, using two-hybrid analysis with deletion mutants, we have localized the binding domain for GpIbalpha in beta -filamin to residues 1862-2148, an area homologous to the GpIbalpha binding domain in ABP-280. beta -Filamin is a new member of the filamin family that may have significance for GpIbalpha function in endothelial cells and platelets.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Glycoprotein (Gp)1 Ibalpha , GpIbbeta , GpIX, and GpV are all members of the leucine-rich glycoprotein superfamily and form a complex in the platelet membrane (1). All four polypeptides of the GpIb complex are also present in human endothelial cells (2). The platelet GpIb complex mediates the adherence of platelets at the site of vascular injury through the binding of GpIbalpha to subendothelial von Willebrand factor (vWF).

In platelets, the GpIb complex is tightly bound to the actin cytoskeleton via an interaction of GpIbalpha with actin-binding protein 280 (ABP-280) (3-5); it can be presumed (but has not been shown) that a similar interaction occurs in endothelial cells (ECs). ABP-280 cDNA has been cloned from a HUVEC cDNA library (6) and mapped to the X chromosome (7, 8). ABP-280 has sometimes been referred to as human non-muscle filamin.

Partial sequence of two other ABP-280-related entities from human sources has been reported. Two partial cDNA fragments of one species, termed actin-binding protein-like protein (ABPL), were cloned by PCR and mapped to chromosome 7; full-length cDNA has not been reported. A second species, termed truncated actin-binding protein (TABP) in one publication (9) and filamin homolog-1 in another (10), has been reported. The TABP open reading frame predicts a protein of only 195 residues, whereas only a 291-amino acid sequence has been reported for filamin homolog-1. However, both sequences are homologous to the COOH-terminal region of ABP-280.

Here, we report the molecular cloning and full sequence of a new human homolog of chicken filamin, which, like ABP-280, associates with the cytoplasmic tail of GpIbalpha . It is present in only small amounts in platelets, but in substantial quantities in ECs. We term this new protein human beta -filamin, reserving the term alpha -filamin for ABP-280.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Two-hybrid Library Screening and Full-length cDNA Cloning-- A DNA fragment coding the cytoplasmic tail of GpIbalpha between residues 1633 and 1976 (11) was amplified from human genomic DNA (because the GpIbalpha gene has no introns in this area), directionally cloned in-frame into the yeast expression vector pAS2-1 (CLONTECH), and confirmed by sequencing. This vector expresses a fusion protein consisting of the cytoplasmic tail of GpIbalpha and the yeast GAL4 DNA-binding domain.

cDNA libraries (CLONTECH) derived from human bone marrow (in pGAD10) and human placenta (in pACT2) were screened in the yeast two-hybrid system. Yeast strain CG-1945 was transformed sequentially with the GpIbalpha tail vector and the library vectors. Transformants were plated on SD/Trp-/Leu-/His- plates, and incubated at 30 °C until colonies appeared. beta -Galactosidase activity of each colony was determined qualitatively in a filter-lift assay. In order to exclude false positives, positive clones were re-introduced into yeast together with either the GpIbalpha bait vector, the pAS2-1 original vector or pLAM5', a vector encoding a human lamin cDNA in the two-hybrid DNA-binding domain vector pGBT9. To obtain the remaining 5' cDNA, a human placenta 5'-STRETCH cDNA library in lambda gt10 (CLONTECH) was screened as described under "Results."

Isolated cDNA inserts were transferred to the sequencing vector pBluescript (Stratagene, La Jolla, CA), and both strands were sequenced using universal primers or synthetic oligonucleotides. Sequencing was performed using Dyedeoxy Terminator Cycle Sequencing kits and a model 377 DNA sequencing system (Applied Biosystems, Foster City, CA).

Sequence Analysis-- We used the BLAST computer program to search the GenBank data base for expressed sequence tags (ESTs) and sequence-tagged sites (STSs) containing sequences identical to those in beta -filamin cDNA. The UNIGENE program was then used to group ESTs and STSs.

Northern Blot Hybridization and RT-PCR-- A human multiple tissue blot was purchased from CLONTECH, and a blot of HUVECs and CHRF-288 cell poly(A)+ RNA was kindly supplied by Dr. Barbara Konkle, Cardeza Foundation, Jefferson Medical College. beta -Filamin mRNA expression was detected with a ~2.6-kb probe from the 5' end of cDNA clone THC-106 (Fig. 1). ABP-280 mRNA expression was detected with a ~2.7-kb (nt 5605-3' end) ABP-280 cDNA clone isolated from the bone marrow library. To confirm the quality of the blots, we used beta -actin as a probe.

For RT-PCR, total RNA from platelets, HUVECs, or the HEL and CHRF-288 cell lines were isolated using Triazol (Life Technologies, Inc.). Each first-strand cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase (Seikagaku America, Rockville, MD) with oligo(dT). PCR was performed using ExTaq polymerase (Panvera, Madison, WI) with a sense primer (5'-TTGAATGGCGCAAAAGGC-3') (nt 7065-7082) and an antisense primer (5'-GCCCACCGTATTTGACAC-3') (nt 7489-7506). These sequences were chosen to amplify beta -filamin and not ABP-280. The 442-bp cDNA fragment obtained was sequenced in order to confirm its origin from beta -filamin mRNA.

Antibody Production and Western Blotting-- Because the first "hinge" region in beta -filamin differs completely from that in ABP-280 (Fig. 4), we synthesized a peptide (TDGEVTAVEEAPVNACPPG) corresponding to that sequence and coupled it to activated keyhole limpet hemocyanin or to activated bovine serum albumin (BSA) (Pierce). The keyhole limpet hemocyanin peptide was used as immunogen. Rabbits were injected every 2-3 weeks, and serum titers were measured on the BSA-peptide-coated ELISA plates. IgG fractions were isolated from serum using protein G-Superose (Amersham Pharmacia Biotech) and affinity-purified on BSA-peptide Sepharose columns.

HUVECs were harvested from human umbilical cords and cultured essentially as described (2). HUVECs were washed with PBS three times before detachment in lifting buffer (0.01 M phosphate, 0.15 M NaCl, 5 mM NaHCO3, 10 mM EDTA, 5 mM EGTA, 0.1% BSA, 1 mM phenylmethylsulfonyl fluoride, pH 7.2). HUVECs were centrifuged at 250×g for 10 min, washed with lifting buffer, and incubated for 30 min at 4 °C with a lysis buffer consisting of 50 mM Tris-HCl, 5 mM EDTA, 5 mM EGTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml DNase I (grade II, bovine pancreas, Boehringer Mannheim), 0.5 mM leupeptin, 0.5 mg/ml benzamidine, 400 KIU/ml aprotinin, pH 7.5. After lysis, 0.5 volume of 3× concentrated SDS sample buffer (without reducing agent) was added. Concentration of ECs in the sample was approximately 5 × 106/ml; aliquots of 20 µl were electrophoresed.

Human platelets were isolated from freshly drawn venous blood, washed twice in PBS containing 2 mM EDTA, 1 mM prostaglandin E1, 0.2% dextrose, and centrifuged at 1,250 g for 10 min. The platelet pellet was suspended directly in 1× sample buffer (without reducing agent) at a platelet concentration of 1 × 109/ml. The non-reduced lysed samples (40 µl) were subjected to SDS-polyacrylamide gel electrophoresis in 6% polyacrylamide gels, after which Western blotting was performed as described (2), using 2 µg/ml polyclonal anti-beta -filamin IgG or 1 µg/ml murine monoclonal anti-ABP-280 antibody mAb-1 (6). mAb-1 was a kind gift from Dr. John Hartwig (Brigham and Women's Hospital, Boston, MA).

Immunohistochemistry-- HUVECs were incubated overnight at 4 °C with a mAb to ABP-280 (mAb-4, kindly supplied by Dr. John Hartwig) or to vWF (Dako, Carpinteria, CA), or an irrelevant control mouse IgG1 antibody (Dako). Bound mouse IgG was detected using a biotinylated horse anti-mouse polyclonal antibody (Vector Labs, Burlingame, CA) followed by avidin conjugated to Texas Red (Leinco Technologies, Inc., Ballwin, MO). After appropriate washing the cells were incubated for 1 h at room temperature with either rabbit polyclonal antibody to the beta -filamin first hinge, rabbit polyclonal antibody to vWF (Biogenex, San Ramon, CA), or rabbit polyclonal control immunoglobulins (Biogenex). Bound rabbit IgG was detected using fluorescein-conjugated goat anti-rabbit IgG (Leinco). Stained HUVECs were visualized by confocal laser scanning microscopy.

Immunofluorescence microscopy for beta -filamin protein was also performed on samples of normal adult breast skin. Briefly, cryostat (5 µm) sections were fixed with acetone for 5 min at -20 °C, air-dried, and incubated with antibody to beta -filamin or rabbit control IgG for 1 h at room temperature. After washing in PBS, the tissue was then incubated with Texas red-conjugated donkey anti-rabbit IgG (Accurate Scientific, Westbury, NY).

Interaction of beta -Filamin and GpIbalpha in Whole Cell Lysates-- Microtiter wells were coated with 100 µl of a 10 µg/ml solution in 0.1 M NaHCO3/Na2CO3, pH 9.6, of either purified anti-GpIbalpha mAb Ib1 (12) (kindly supplied by Dr. Zaverio Ruggeri, Scripps Research Institute, La Jolla, CA) or normal mouse IgG (Pel-Freez, Rogers, AR). After washing three times with PBS, the wells were blocked with 3% BSA-PBS. Platelets and HUVECs were lysed with lysis buffer at concentrations of 1.5 × 109/ml and 5 × 106/ml, respectively, and centrifuged at 100,000 × g for 90 min, in order to remove cytoskeleton actin filaments (3). Wells were incubated with serial dilutions of either platelet or HUVEC supernatant for 4 h at room temperature and then with fresh supernatant overnight at 4 °C. The wells were washed six times and incubated for 1 h with either 100 µl of a 10 µg/ml solution in 3% BSA-PBS of anti-GpIbalpha polyclonal IgG (13), affinity-purified polyclonal anti-beta -filamin IgG, or pre-immune rabbit IgG. The wells were then washed six times with PBS, incubated with 100 µl of phosphatase-labeled goat anti-rabbit IgG (Kirkegaard and Perry, Gaithersburg, MD), washed six times, and developed using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium phosphatase substrate (Kirkegaard and Perry). Experiments were done in duplicate.

Identification of the beta -Filamin Domain Binding to the Cytoplasmic Tail of GpIbalpha -- Deletion mutants in the vector pACT2 were made using cloning sites of the vector and internal restriction sites of beta -filamin (ApaI at nt 5708, NcoI at nt 6571 and nt 7462, and EcoRI at nt 7341) (Fig. 10). Because all inserts except clone 1 lacked stop codons in their sequence, expression of clones 2-6, which required use of vector stop codons, resulted in products containing 10 additional amino acids. Each mutant was co-transformed into yeast with the GpIbalpha bait vector and processed for quantitation of beta -galactosidase activity using a liquid culture assay with o-nitrophenyl-beta -D-galactoside (Sigma) as substrate. beta -Galactosidase units were calculated as recommended by the supplier (CLONTECH).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Isolation of beta -Filamin cDNA-- Using as bait the cytoplasmic tail of GpIbalpha , we first screened a human bone marrow two-hybrid library. Of 4 × 106 clones screened, we isolated six His+/LacZ+ clones, each with the same size ~2.7-kb insert. The sequence of one of these clones was identical to the sequence of ABP-280 (6). Because ABP-280 cDNA has an EcoRI site within this sequence, we compared the cleavage patterns of the remaining five clones with that of the sequenced clone, and found them to be identical.

We then screened a human placental two-hybrid library. Of 5 × 105 clones screened, we isolated eight His+/LacZ+ clones. To confirm their positive nature, we re-introduced these clones into yeast together with either the GpIbalpha bait vector, the pAS2-1 original vector or pLAM5' (a vector containing human lamin, used as a control). Transactivation of HIS3 and lacZ was observed only in the presence of the GpIbalpha bait vector.

One of those clones, THC-106 (Fig. 1), containing a 4.7-kb insert terminating in poly(A) was sequenced. The other seven clones also contained 4.7-kb inserts and showed the same restriction enzyme digestion pattern as THC-106. The sequence of THC-106 suggested that this was a partial cDNA encoding a new filamin homolog.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Sequencing strategy for beta -filamin and alignment of overlapping cDNA clones. THC-106 is the original clone isolated by two-hybrid screening. Each clone from the phage library is indicated as FPC. T23 is the cDNA clone PCR-amplified using a 5' primer derived from the EST52361 clone and a 3' primer derived from THC-106. Probes 1, 2, and 3 were derived from clones THC-106, T23, and FPC-7, respectively.

To obtain the remaining 5' sequence, a human placental cDNA library in lambda gt10 was screened, using initially a probe (probe 1, Fig. 1) derived from THC-106, resulting in the isolation of clones FPC-1 and FPC-3. In order to screen further 5', we constructed a primer based on the sequence of an EST clone (EST52361, TIGR/ATCC, Rockville, MD) that had been submitted as filamin-like cDNA. We designed a sense primer (5'-CACCGTGAAGTGTGTAGG-3') according to this EST sequence and an antisense primer (5'-GACAATGGCTCTTTTGGG-3') according to the two-hybrid cDNA clone (THC-106). Using these primers, the cDNA fragment T23 was amplified from HUVEC cDNA and cloned in pGEM-T Easy vector (Promega, Madison, WI). By sequencing, we confirmed that the sequence of the 3' end was identical to that of the 5' end of THC-106. We then used the 5' half of T23 as probe 2, and isolated clones FPC-5 and FPC-7. Although the sequence of FPC-7 encodes the expected first methionine, based on homology to ABP-280, no in-frame termination codon was found upstream of this methionine. In order to identify the most 5' sequence, we used probe 3 derived from clone FPC-7 and isolated three clones, FPC-14, FPC-15, and FPC-17, spanning up to nucleotides number 6, 8, and 31, respectively, of FPC-7. THC-106 and the seven phage clones shown in Fig. 1 were overlapping and spanned 9.4 kb.

As shown in Fig. 2, the beta -filamin sequence predicts a polypeptide consisting of 2602 amino acids. The methionine designated as the initiation codon was chosen for several reasons. First, the clone FPC-7 was isolated from a library designed to include the most 5' upstream sequences of cDNAs and four different clones we isolated reached up to nearly the same upstream site. Second, when we attempted to amplify the most 5' sequence of the beta -filamin cDNA by PCR from a human placental library (in lambda gt10), using a sense primer derived from the phage arm and an antisense primer derived from beta -filamin (nt 312-329), we obtained a PCR product that was 8 nucleotides shorter than FPC-7 (data not shown). Third, the predicted amino acid sequence NH2-terminal to this methionine has no homology with other actin-binding proteins, whereas the sequence COOH-terminal to this methionine contains an actin-binding domain signature at residues 18-27. Moreover, as we show, the molecular mass of beta -filamin determined by Western blotting is about 280 kDa, consistent with the 278-kDa molecular mass predicted from our cDNA sequence. However, the proposed initiation site is not flanked by an initiation consensus sequence (CCA/GCC) (14). Thus, to confirm the initiation site it will be necessary to obtain beta -filamin genomic sequence.


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 2.   Predicted amino acid sequence of beta -filamin. The two underlined regions indicate the actinin-type actin-binding domain signatures 1 (residues 18-27) and 2 (94-118). Alignment of repeats is based on homology with ABP-280. The two hinge regions are indicated.

Homology between beta -Filamin, CRF, and ABP-280-- beta -filamin shows strong homology to CRF (15) and human ABP-280 (6) over its entire sequence, with the exception of the first hinge region, and with other actin-binding proteins, including spectrins, alpha -actinin and dystrophins, in its amino terminus (residues 1-275). beta -Filamin, ABP-280, and CRF all contain 24 internally homologous repeats (Fig. 3); beta -filamin and ABP-280 contain two hinge regions, whereas CRF contains only the more COOH-terminal of the two hinge regions. Furthermore, although the second hinge regions of beta -filamin and ABP-280 are 44% identical, the first hinge regions of the two proteins are entirely dissimilar (Fig. 4). Excluding the first hinge region, the amino acid sequence of beta -filamin is 70% identical with ABP-280, but 83% identical with CRF, whereas ABP-280 is 66% identical with CRF. The partial sequence of ABPL (the chromosome 7 homolog) is 68% identical with CRF and resembles CRF in lacking a first hinge; the available sequence does not extend sufficiently 3' to identify the second hinge region (8).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Structural comparison between chicken retinal filamin, ABP-280, and beta -filamin. Numbers above the bars indicate the amino terminus, the end of the actin-binding domain and the carboxyl terminus. Numbers within the bars indicate the tandem repeat number.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   Comparison of the first hinge region of beta -filamin and homologous proteins. The peptide sequence of ABPL is derived from the cDNA sequence published by Maestrini et al. (8). Boxed amino acids indicate identity in at least two of the four sequences. Single dots indicate adjustments in alignment for missing residues. The single line above part of the sequence of beta -filamin indicates the peptide sequence used for antibody preparation.

Chromosomal Localization of beta -Filamin-- During analysis of beta -filamin sequence data, we observed that an STS marker, WI-8718, was part of the gene. This marker has been linked to microsatellite marker D3S1295 in 3p14.3-p21.1 by analysis of the GeneBridge 4 Radiation Hybrid Panel at the Whitehead Institute.2 The beta -filamin gene maps between D3S1313 and D3S1295.

Tissue and Cellular mRNA Expression of beta -Filamin-- Northern blot analysis revealed that beta -filamin (Fig. 5A), like ABP-280 (Fig. 5B), is constitutively expressed in many adult human tissues. However, there appear to be some differences in the tissue-specific expression of the two species (for example, kidney and pancreas versus heart and lung). Two different-sized beta -filamin mRNA transcripts were detected (Fig. 5A), one somewhat larger than 9.5 kb and one somewhat smaller than 9.5 kb, the latter almost identical in size to the ABP-280 transcript (Fig. 5B). These differences are most likely a result of the use of two different poly(A) signal sequences, one located just beyond the stop codon and one located 1.5 kb further 3' (data not shown). The cDNA that was isolated from the two-hybrid library used the later poly(A) signal sequence. However, we also found several EST clones (H01996, W40252, W45289, W52463, AA056341, T67924) that use the earlier signal.


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 5.   Northern blot analysis of beta -filamin and ABP-280. Human adult tissues (A and B) and HUVECs and CHRF-288 poly(A)+ RNA (C and D) were probed with beta -filamin cDNA (A and C) or ABP-280 cDNA (B and D). The two beta -filamin mRNA species are indicated by arrows.

As shown in Fig. 5 (C and D), Northern blot analysis detects ABP-280 and beta -filamin mRNA in HUVECs, but only ABP-280 mRNA in CHRF-288. As shown in Fig. 6, by RT-PCR, beta -filamin mRNA expression was observed in platelets, the megakaryocytic cell line CHRF-288 and the erythroleukemic HEL cell line, as well as in HUVECs. The 442-bp RT-PCR products were sequenced and were identical to the expected beta -filamin sequence. In order to confirm that these 442-bp products did not arise from genomic DNA, we amplified genomic DNA using the same primers and observed an approximately 8.5-kb product. Sequence of this product demonstrated the presence of at least two introns (data not shown). From these results, we conclude that beta -filamin mRNA is expressed in megakaryocytes (and can be found in platelets), but that expression in megakaryocytes is considerably less than in endothelial cells.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 6.   RT-PCR amplification of beta -filamin mRNA. The 442-bp cDNA fragments were obtained by RT-PCR using beta -filamin-specific primers.

Detection of beta -Filamin Protein-- By Western blotting with the antibody to beta -filamin's unique first hinge, we detected substantial amounts of 280-kDa protein in HUVECs, but only minimal amounts in platelets (Fig. 7). This band was completely eliminated by pre-incubation of the antibody with 10 µg/ml first hinge peptide (data not shown). The lower molecular mass bands observed were also seen in the absence of the specific hinge antibody (data not shown). ABP-280 protein was expressed in substantial amounts in both cell types. Thus it appears that in platelets ABP-280 predominates, whereas relatively similar amounts of the two proteins are present in HUVECs.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 7.   Analysis of protein expression in HUVECs and platelets by Western blotting. Numbers to the left indicate molecular sizes of prestained standards.

Immunohistochemistry-- As shown in Fig. 8a, beta -filamin is detectable in normal human dermal vessels; the vessel shown here is a venule. The pattern is the same as that seen for GpIbalpha (data not shown). As shown in Fig. 8b, by confocal microscopy beta -filamin in cultured HUVECs is localized primarily on the cytoplasmic aspect of the cell and nuclear membranes, but also appears in a more linear distribution within the cytoplasm; ABP-280 shows a similar pattern (data not shown). In contrast, the punctate staining of von Willebrand factor is shown in Fig. 8c.


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 8.   Immunofluorescence microscopy. a, normal human dermis stained for beta -filamin; b and c, cultured HUVECs stained for beta -filamin (b) or vWF (c).

Association between GpIbalpha and beta -Filamin-- We used an antigen-capture ELISA assay to detect the association between GpIbalpha and beta -filamin in 100,000 × g supernatants of Triton extracts of platelets and HUVECs. The anti-GpIbalpha mAb Ib1 captured GpIbalpha (Fig. 9, open bars) from both platelet and HUVEC lysates in a dose-dependent manner; the lesser amount captured from HUVECs is consistent with the lower level of GpIbalpha protein expression in HUVECs than in platelets (2). The anti-beta -filamin polyclonal antibody detected beta -filamin associated with the GpIbalpha captured by mAb Ib1 (Fig. 9, diagonally striped bars). The solid bars depict controls using pre-immune rabbit IgG in place of the primary antibodies. Because the antibodies used for the platelet and EC supernatants were identical, we compared the absorbance ratios of captured beta -filamin to GpIbalpha for platelets and ECs. The beta -filamin:GpIbalpha ratios for the 1:2 dilutions (after subtracting the pre-immune rabbit IgG control) were 0.08 and 1.34 for platelets and ECs, respectively, suggesting that a much larger fraction of EC GpIbalpha than platelet GpIbalpha is bound to beta -filamin. When normal mouse IgG was used for coating the ELISA wells, no beta -filamin was captured (data not shown).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 9.   Antigen-capture ELISA. Antigens were captured on microtiter wells coated with anti-GpIbalpha mAb Ib1. Each experiment was performed in duplicate. Open bars, captured GpIbalpha , detected with polyclonal anti-glycocalicin; diagonally striped bars, captured beta -filamin, detected by the polyclonal anti-hinge antibody; solid bars, pre-immune rabbit IgG control. Abscissa, Triton lysate dilution; ordinate, absorbance at 405 nm.

Localization of the Domain of beta -Filamin Binding to the Cytoplasmic Tail of GpIbalpha -- To determine the domain of beta -filamin interacting with the cytoplasmic tail of GpIbalpha , we performed two-hybrid analysis. Six constructs were prepared in pACT2, as indicated in Fig. 10. Each construct expressed a fusion protein consisting of the yeast GAL4-activation domain and one cDNA fragment. After co-transformation of each construct with the GpIbalpha bait vector, we analyzed expression of HIS3 and lacZ by growth selection and beta -galactosidase assay, respectively. As shown in Fig. 10, fusion constructs 1, 2, and 3 were positive in both assays, whereas construct 4, lacking residues 1862-2148, was negative. These results indicate that the GpIbalpha binding domain in beta -filamin is located within residues 1862-2148 (repeats 17-20). This GpIbalpha binding domain in ABP-280 has been reported to localize to residues 1850-2136 (repeats 17-19) (16). Constructs 5 and 6 induced HIS3 activity and construct 5 also induced a small amount of lacZ activity in the filter assay; however, they did not induce lacZ activity in the quantitative assay using o-nitrophenyl-beta -D-galactoside. Because X-gal detection in the filter assay is ~106 times more sensitive than o-nitrophenyl-beta -D-galactoside, it is still possible that the polypeptide sequence between 2406 and 2445 includes another weak binding site to GpIbalpha .


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 10.   Localization by the two-hybrid system of the beta -filamin domain binding to the cytoplasmic tail of GpIbalpha . The upper bar depicts the carboxyl half of beta -filamin. The six mutants are shown below. In the beta -galactosidase (beta -Gal) filter assay, +++ indicates deep blue color development within 15 min and + indicates weak blue color appearance after 60 min.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The term "filamin" was introduced by Singer's laboratory (17) to describe a 250-kDa protein isolated from chicken gizzard, normally present as a dimer (18), that is capable of inducing actin polymerization (19). Filamins have been isolated from a number of organs and cell types from chicken, human and other species (20-24), but most biochemical studies have been performed using filamins isolated from chicken gizzard, rabbit macrophage or human uterus. In 1990, Gorlin et al. (3) reported the sequence of a human endothelial cell cDNA specifying a protein which they termed actin-binding protein 280, or ABP-280. This protein is probably identical to the actin-binding protein purified from human uterus, based on limited amino acid sequence (25) and on cross-reactivity with monoclonal antibodies (6), and which exists as a 560-kDa dimer (6). Because of its 280-kDa size, its ability to dimerize, and its ability to induce actin polymerization, ABP-280 has often been referred to as human non-muscle filamin, although it is present in smooth (uterine) muscle (6, 25) and in skeletal muscle (Ref. 8, this paper, Fig. 5). ABP-280 contains a 274-residue amino-terminal actin-binding domain, followed by 24 internally homologous repeats among which are intercalated two hinge regions, one of 32 residues between repeats 15-16 and one of 34 residues between repeats 23-24 (these figures are based on our sequence alignment of ABP-280, beta -filamin, and CRF). Gorlin et al. (6) localized the site of dimerization of ABP-280 to repeat 24. Electron microscopic studies of human uterine actin-binding protein by these investigators suggested that the first hinge region might allow the ABP-280 dimer to form a "Y," with the COOH-terminal halves of the protein forming a rigid dimeric structure and the NH2-terminal halves, containing the actin-binding domains, forming the separated ends of the Y. The two hinge regions were found to be sites of calpain cleavage, resulting in the formation of 185-, 90-, and 10-kDa fragments (6, 26).

In 1993, Barry and co-workers (15) cloned and sequenced chicken retinal filamin and found it to be highly homologous to ABP-280, with the major exception that the CRF sequence lacked the more NH2-terminal of the two hinge regions present in ABP-280 (15). If one assumes that CRF and chicken gizzard filamin are identical and that human ABP-280 and rabbit actin-binding protein are also identical, this difference in structure may account for the observations that 1) chicken gizzard filamin produces parallel actin bundles (27) whereas human ABP-280 induces the formation of branched actin polymers (28), and that 2) chicken gizzard filamin is cleaved by calpain into only two fragments: 240 and 10 kDa (27).

Other reports suggest the existence in a single species of more than one filamin. For example, Gomer and Lazarides (29, 30) described an apparent switch in filamin types during chick skeletal muscle development, and Mangeat and Burridge (31) described the presence of two filamin types in HeLa cells. In addition, two other proteins showing homology with CRF and ABP-280 have been isolated from chicken gizzard, the 450-kDa "fulcin" (32), and the 260-kDa "ABP-260" (33). Partial cDNA sequence is available for each, although in neither case is sequence available for the areas corresponding to the hinge regions.

In this paper, we describe a new 280-kDa protein, beta -filamin, highly homologous to ABP-280 and CRF. beta -Filamin contains the same NH2-terminal actin-binding signatures present in the other two proteins as well as in alpha -actinin (34), beta -spectrin (35), and dystrophin (36). Following the actin-binding domain, beta -filamin shares with ABP-280 and CRF a structure (not present in alpha -actinin, beta -spectrin, and dystrophin) consisting of 24 internally homologous repeats (Figs. 2 and 3). However, beta -filamin differs from the other two sequenced filamins in the region of the first of the two hinges; its first hinge sequence is totally distinct from that of ABP-280 (Fig. 4), whereas the reported CRF sequence lacks a first hinge completely. beta -Filamin does not contain in its first hinge the calpain cleavage sequence PQYdown-arrow TYA present in the first hinge of ABP-280 (6) and is only 44% identical in the second hinge region, suggesting that the two proteins may have different calpain cleavage patterns, a possibility currently under investigation in our laboratory.

Three other human sequences have been reported that are closely related to ABP-280 and beta -filamin.

1) In 1993, Leedman et al. (9), using immunoglobulins from Graves' disease patients, reported the cloning from a human thyroid library of a cDNA specifying a 195-amino acid protein homologous to the COOH terminus of ABP-280. This predicted protein has been termed TABP or thyroid autoantigen. It was suggested that TABP may function in concert with ABP in the thyroid to link integral membrane glycoproteins, such as the thyroid-stimulating hormone receptor, to cytoskeletal actin and thus play a role in signal transduction. However, TABP protein has not been identified in thyroid tissue, and further characterization of TABP has not been done. TABP and beta -filamin are probably transcribed from the same gene, because the sequence of TABP and of the corresponding region of beta -filamin are almost identical, and the genetic locus of TABP has been identified as chromosome 3 (UniGene accession number Hs. 81008).

2) Very recently, Zhang and co-workers (10), using the cytoplasmic loop region of presenilin-1 as bait in a two-hybrid screen, isolated cDNA fragments encoding the 358 COOH-terminal amino acids of ABP-280, as well as an unknown 291-amino acid sequence showing 69% identity with ABP-280, which they termed "filamin homolog 1" (Fh1). They mapped the Fh1 gene to chromosome 3. The sequence they reported is identical to the COOH-terminal 291 amino acids of beta -filamin except for two residues (L2312M and G2382E, using the beta -filamin residue numbers), making it very likely that it represents the COOH-terminal region (most of repeat 22, repeat 23, the second hinge, and repeat 24) of beta -filamin.

3) Maestrini et al. (8) reported two partial cDNA sequences, mapping to chromosome 7, that are homologous to repeats 4-6 and 15-19 of ABP-280. The second of these cDNAs contains the region around the first hinge but lacks any first hinge sequence (Fig. 4). By Northern blotting, an mRNA similar in size to ABP-280 was identified exclusively in skeletal and cardiac muscle. We have confirmed by RT-PCR the existence of such a species and its limited tissue distribution.3 We are currently attempting to isolate and sequence a larger region of this protein, particularly the area that spans the second hinge region, to establish the relationship between this entity and the other filamins.

Filamin-type proteins are not limited to vertebrates. A closely related actin-binding protein has been identified in Dictyostelium discoideum (37). This 120-kDa protein, referred to as ABP-120, consists of an NH2-terminal actin-binding domain followed by six filamin-like 100 residue repeats, but lacks any hinge regions, and exists as a 240-kDa homodimer (37). The three-dimensional structure of repeat 4 has been determined by NMR spectroscopy and consists of seven beta -sheets arranged in an immunoglobulin-like fold (38). This is the only reported structural analysis of a filamin repeat. ABP-120 appears to modulate pseudopod extension in D. discoideum (39).

These studies and the present report define a group of filamin-related proteins, which we suggest be termed the filamin superfamily, on the basis of homology with chicken filamin. Within this superfamily, we suggest naming well characterized members by species and by order of discovery and full characterization. Thus, ABP-280 would be termed human alpha -filamin and our protein would be called human beta -filamin. The term "human gamma -filamin" should probably be reserved for the chromosome 7 product.

The filamins appear to function as promoters of actin polymerization and to connect cell membrane constituents to the actin cytoskeleton. The former function has been demonstrated for filamins from several species (40). The latter function has been implied by several immunohistochemical localization studies in chickens (29, 32) but investigated in detail only for human ABP-280 (alpha -filamin). The first membrane protein shown to interact with ABP-280 (alpha -filamin) was GpIbalpha (3, 26, 41). The interaction appears to involve residues 536-568 of the 96-residue cytoplasmic tail of GpIbalpha (4, 5) and an area within residues 1850-2136 (from the end of repeat 16 to the beginning of repeat 20) of ABP-280 (alpha -filamin) (16). The interaction of beta -filamin with the cytoplasmic tail of GpIbalpha involves an area within residues 1862-2148 (from the middle of repeat 17 to the middle of repeat 20). Therefore, on the basis of the homology between these two filamins, it is likely that the GpIbalpha binding sequence is somewhere between the middle of repeat 17 and the beginning of repeat 20.

In addition to its interaction with GpIbalpha , ABP-280 (alpha -filamin) has been shown to associate with other membrane proteins, including the high affinity IgG receptor Fcgamma RI (42), the beta 2-integrin CD18 subunit (43), presenilin 1 (10), tissue factor (44), and the calcium-dependent serine endoprotease furin (45), as well as with the cytoplasmic protein SEK-1 (46). Although the binding sites for Fcgamma RI and beta 2-integrin are not known, the regions of ABP-280 (alpha -filamin) binding to SEK-1 and furin are contained within residues 2282-2454 (repeats 21-23) and residues 1490-1607 (repeats 13-14), respectively. Furthermore, our data and the data of Zhang et al. (10) identify repeats 17-20 and 22-24 of beta -filamin as distinct binding regions for the cytoplasmic tails of GpIbalpha and presenilin-1, respectively. Thus, despite their strong internal homology, sufficient unique information resides in different repeats to create specific binding sites for a number of proteins. We are currently investigating the interactions of beta -filamin with other cellular constituents.

The functions of the filamins are not fully known, but ABP-280 has been demonstrated to play a crucial role in cellular cytoskeletal and membrane organization (47), and may also be critical for membrane expression of some receptors (48). We have published evidence that ECs synthesize and express on their membranes all four components of the GpIb/IX/V complex, although the membrane density of these components in ECs is substantially lower than in platelets (2). beta -Filamin is expressed in only trace amounts in platelets, and we observed only small amounts of GpIbalpha bound to beta -filamin, consistent with the observations of Ezzell et al. that as much as 90% of platelet GpIbalpha is bound to ABP-280 (alpha -filamin) (26). However, substantial amounts of both beta -filamin and ABP-280 (alpha -filamin) are present in ECs, and in ECs we detected relatively large amounts of beta -filamin bound to GpIbalpha . The homology between beta -filamin and ABP-280, as well as our findings and those of Zhang et al. (10), suggest that these two proteins share a number of functions. On the other hand, the differences in structure, particularly in the hinge regions, suggest that beta -filamin may have unique effects on membrane-cytoskeletal interactions, an area under active investigation in our laboratory.

    ACKNOWLEDGEMENTS

Peptides were synthesized at The University of Virginia Biomolecular Research Facility. Nucleic acid sequencing and confocal microscopy were performed at Core Facilities of the Kimmel Cancer Institute, Jefferson Medical College. We are grateful to Dr. Marcia Monteiro and Diana Whitaker-Menezes for their expert technical assistance and to Dr. Kay Heubner (Kimmel Cancer Institute) for helpful discussions.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant HL09163 (to S. S. S.) and fellowships from the Brandywine Valley Hemophilia Foundation and the Delaware Valley Chapter of the National Hemophilia Foundation (to T. T.). This work was presented in part at the 39th Annual Meeting of the American Society of Hematology, Dec. 6-9, 1997, San Diego, CA, and published in abstract form (Takufuta, T., Wu, G., and Shapiro, S. S. (1997) Blood 90, 290a (abstr.)).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF042166.

To whom correspondence should be addressed: Cardeza Foundation for Hematologic Research, Jefferson Medical College, 1015 Walnut St., Philadelphia, PA 19107. Tel.: 215-955-7786; Fax: 215-955-2366; E-mail: Sandor.Shapiro{at}mail.tju.edu.

1 The abbreviations used are: Gp, glycoprotein; ABP, actin-binding protein; ABPL, ABP-like protein; CRF, chicken retinal filamin; EC, endothelial cell; EST, expressed sequence tag; HUVEC, human umbilical vein endothelial cell; STS, sequence-tagged site; TABP, truncated ABP; vWF, von Willebrand factor; PCR, polymerase chain reaction; RT, reverse transcriptase; PBS, phosphate-buffered saline; kb, kilobase pair(s); bp, base pair(s); nt, nucleotide(s); BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; mAb, monoclonal antibody.

2 Information is available on the World Wide Web (http://wwwgenome.wi.mit.edu).

3 T. Takafuta and S. S. Shapiro, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Clemetson, K. J. (1997) Thromb. Haemostasis 78, 266-270[Medline] [Order article via Infotrieve]
  2. Wu, G., Essex, D. W., Meloni, F. J., Takafuta, T., Fujimura, K., Konkle, B. A., and Shapiro, S. S. (1997) Blood 90, 2660-2669[Abstract/Free Full Text]
  3. Andrews, R. K., and Fox, J. E. B. (1991) J. Biol. Chem. 266, 7144-7147[Abstract/Free Full Text]
  4. Andrews, R. K., and Fox, J. E. B. (1992) J. Biol. Chem. 267, 18605-18611[Abstract/Free Full Text]
  5. Cunningham, J. G., Meyer, S. C., and Fox, J. E. B. (1996) J. Biol. Chem. 271, 11581-11587[Abstract/Free Full Text]
  6. Gorlin, J. B., Yamin, R., Egan, S., Stewart, M., Stossel, T. P., Kwiatkowski, D. J., and Hartwig, J. H. (1990) J. Cell Biol. 111, 1089-1105[Abstract]
  7. Gorlin, J. B., Henske, E., Warren, S. T., Kunst, C. B., D'Urso, M., Palmieri, G., Hartwig, J. H., Bruns, G., and Kwiatkowski, D. J. (1993) Genomics 17, 496-498[CrossRef][Medline] [Order article via Infotrieve]
  8. Maestrini, E., Patrosso, C., Mancini, M., Rivella, S., Rocchi, M., Repetto, M., Villa, A., Frattini, A., Zoppe, M., Vezzoni, P., and Toniolo, D. (1993) Hum. Mol. Genet. 2, 761-766[Abstract]
  9. Leedman, P. J., Faulkner, J. B., Cram, D. S., Harrison, P. J., West, J., O'Brien, E., Simpson, R., Coppel, R. L., and Harrison, L. C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5994-5998[Abstract]
  10. Zhang, W., Han, S. W., McKeel, D. W., Goate, A., and Wu, J. Y. (1998) J. Neurosci. 18, 914-922[Abstract/Free Full Text]
  11. Lopez, J. A., Chung, D. W., Fujikawa, K., Hagen, F. S., Papayannopoulou, T., and Roth, G. J. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5616-5619
  12. Handa, M., Titani, K., Holland, L. Z., Roberts, J. R., and Ruggeri, Z. M. (1986) J. Biol. Chem. 261, 12579-12585[Abstract/Free Full Text]
  13. Wu, G., Meloni, F. J., and Shapiro, S. S. (1996) Blood 87, 2782-2787[Abstract/Free Full Text]
  14. Kozak, M. (1984) Nucleic Acids Res. 12, 857-872[Abstract]
  15. Barry, C. P., Xie, J., Lemmon, V., and Young, A. P. (1993) J. Biol. Chem. 268, 25577-25586[Abstract/Free Full Text]
  16. Meyer, S. C., Zuerbig, S., Cunningham, C. C., Hartwig, J. H., Bissell, T., Gardner, K., and Fox, J. E. B. (1997) J. Biol. Chem. 272, 2914-2919[Abstract/Free Full Text]
  17. Wang, K., Ash, J. F., and Singer, S. J. (1975) Proc. Natl. Acad. Sci. U. S. A. 72, 4483-4486[Abstract]
  18. Wang, K. (1977) Biochemistry 16, 1857-1865[Medline] [Order article via Infotrieve]
  19. Wang, K., and Singer, S. J. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 2021-2025[Abstract]
  20. Hartwig, J. H., and Stossel, T. P. (1975) J. Biol. Chem. 250, 5696-5705[Abstract]
  21. Boxer, L. A., and Stossel, T. P. (1976) J. Clin. Invest. 57, 964-976[Medline] [Order article via Infotrieve]
  22. Hartwig, J. H., and Stossel, T. P. (1981) J. Mol. Biol. 145, 563-581[Medline] [Order article via Infotrieve]
  23. Rosenberg, S., Stracher, A., and Lucas, R. C. (1981) J. Cell Biol. 91, 201-211[Abstract]
  24. Weihing, R. R. (1983) Biochemistry 22, 1839-1847[Medline] [Order article via Infotrieve]
  25. Hock, R. S., Davis, G., and Speicher, D. W. (1990) Biochemistry 29, 9441-9451[Medline] [Order article via Infotrieve]
  26. Ezzell, R. M., Kenney, D. M., Egan, S., Stossel, T. P., and Hartwig, J. H. (1988) J. Biol. Chem. 263, 13303-13309[Abstract/Free Full Text]
  27. Davies, P. J., Wallach, D., Willingham, M. C., Pastan, I., Yamaguchi, M., and Robson, R. M. (1978) J. Biol. Chem. 253, 4036-4042[Abstract]
  28. Hartwig, J. H., Tyler, J., and Stossel, T. P. (1980) J. Cell Biol. 87, 841-848[Abstract]
  29. Gomer, R. H., and Lazarides, E. (1981) Cell 23, 524-532[Medline] [Order article via Infotrieve]
  30. Gomer, R. H., and Lazarides, E. (1983) J. Cell Biol. 96, 321-329[Abstract]
  31. Mangeat, P. H., and Burridge, K. (1983) Cell Motil. 3, 657-669[Medline] [Order article via Infotrieve]
  32. Terasaki, A. G., Nakagawa, H., Kotani, E., Mori, H., and Ohashi, K. (1995) J. Cell Sci. 857-868
  33. Tachikawa, M., Nakagawa, H., Terasaki, A. G., Mori, H., and Ohashi, K. (1997) J. Biochem. (Tokyo) 122, 314-321[Abstract]
  34. Millake, D. B., Blanchard, A. D., Patel, B., and Critchley, D. R. (1989) Nucleic Acids Res. 17, 6725[Medline] [Order article via Infotrieve]
  35. Hu, R. J., Watanabe, M., and Bennett, V. (1992) J. Biol. Chem. 267, 18715-18722[Abstract/Free Full Text]
  36. Koenig, M., Monaco, A. P., and Kunkel, L. M. (1988) Cell 53, 219-226[Medline] [Order article via Infotrieve]
  37. Noegel, A. A., Rapp, S., Lottspeich, F., Schleicher, M., and Stewart, M. (1989) J. Cell Biol. 109, 607-618[Abstract]
  38. Fucini, P., Renner, C., Herberhold, C., Noegel, A. A., and Holak, T. A. (1997) Nat. Struct. Biol. 4, 223-230[CrossRef][Medline] [Order article via Infotrieve]
  39. Cox, D., Ridsdale, J. A., Condeelis, J., and Hartwig, J. (1995) J. Cell Biol. 128, 819-835[Abstract]
  40. Weihing, R. R. (1985) Can. J. Biochem. Cell Biol. 63, 397-413[Medline] [Order article via Infotrieve]
  41. Fox, J. E. B. (1985) J. Biol. Chem. 260, 11970-11977[Abstract/Free Full Text]
  42. Ohta, Y., Stossel, T. P., and Hartwig, J. H. (1991) Cell 67, 275-282[Medline] [Order article via Infotrieve]
  43. Sharma, C. P., Ezzell, R. M., and Arnaout, M. A. (1995) J. Immunol. 154, 3461-3470[Abstract/Free Full Text]
  44. Ott, I., Fischer, E. G., Miyagi, Y., Mueller, B. M., and Ruf, W. (1998) J. Cell Biol. 140, 1241-1253[Abstract/Free Full Text]
  45. Liu, G., Thomas, L., Warren, R. A., Enns, C. A., Cunningham, C. C., Hartwig, J. H., and Thomas, G. (1997) J. Cell Biol. 139, 1719-1733[Abstract/Free Full Text]
  46. Marti, A., Luo, Z., Cunningham, C., Ohta, Y., Hartwig, J., Stossel, T. P., Kyriakis, J. M., and Avruch, J. (1997) J. Biol. Chem. 272, 2620-2628[Abstract/Free Full Text]
  47. Cunningham, C. C., Gorlin, J. B., Kwiatkowski, D. J., Hartwig, J. H., Janmey, P. A., Byers, H. R., and Stossel, T. P. (1992) Science 255, 325-327[Medline] [Order article via Infotrieve]
  48. Meyer, S. C., Sannan, D. A., and Fox, J. E. B. (1998) J. Biol. Chem. 273, 3013-3020[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.